SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

01 Apr 2019 Evaluate

Lupin has informed that it has enclosed a Press Release as regards launch of Tadalafil Tablets USP, 2.5 mg, 5 mg, 10 mg, and 20 mg for which US FDA approval was received earlier. This is considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. 2015.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2494.40 -8.50 (-0.34%)
10-Jul-2026 13:38 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1930.50
Dr. Reddys Labs. 1247.10
Cipla 1440.95
Zydus Lifesciences 1149.05
Lupin 2494.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: